- ￥1480
- EK-Bioscience
- CCC-Y1358
- 2025年07月12日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
MKN45、MKN-45、MKN45细胞、MKN-45细胞、MKN45人胃癌细胞
Cell line name MKN45
Synonyms MKN-45; MKN 45
Accession CVCL_0434
Resource Identification Initiative To cite this cell line use: MKN45 (RRID:CVCL_0434)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR39 cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Population: Japanese.
Characteristics: MET-amplified, contains 12-13 copies of the gene (PubMed=29435981).
Doubling time: 30-33 hours (PubMed=3962675); 33 hours (PubMed=29435981); 30-38 hours (CelloPub=CLPUB00584); 16 hours (PubMed=2105279); ~60 hours (DSMZ=ACC-409).
Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Caution: Was indicated not to have a TP53 mutation in PubMed=1370612 and PubMed=15900046.
Misspelling: MKN46; Cosmic=968349.
Misspelling: MNK-45; Note=Occasionally.
Misspelling: MNK45; Note=Occasionally.
Misspelling: NKM-45; Note=Occasionally.
Misspelling: NKM45; Note=Occasionally.
Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)
PubMed=9247707; DOI=10.1080/15216549700202901
Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.
Expression of bone morphogenetic proteins of human neoplastic epithelial cells.
Biochem. Mol. Biol. Int. 42:497-505(1997)
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)
PubMed=9665481; DOI=10.1016/S0002-9440(10)65561-7; PMCID=PMC1852940
Paciucci R., Vila M.R., Adell T., Diaz V.M., Tora M., Nakamura T., Real F.X.
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Am. J. Pathol. 153:201-212(1998)
PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x
Yokozaki H.
Molecular characteristics of eight gastric cancer cell lines established in Japan.
Pathol. Int. 50:767-777(2000)
PubMed=11314020; DOI=10.1038/sj.onc.1204160
Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T., Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.
Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1.
Oncogene 20:869-873(2001)
PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)
PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020
Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., Inazawa J.
Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.
Cancer Sci. 96:100-110(2005)
PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)
PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)
PubMed=15901131; DOI=10.1016/j.prp.2005.01.002
Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.
Pathol. Res. Pract. 201:109-115(2005)
PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002
Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T., Noh S.H., Rha S.Y.
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.
Genomics 93:52-61(2009)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由上海酶研生物科技有限公司提供；
*发表【英文论文】请标注：From Shanghai EK-Bioscience Biotechnology Co., Ltd.
细胞治疗是细胞和基因治疗的重要组成部分，它通过使用特定类型的细胞来修复、替换或调节受损的组织和器官。在细胞治疗中，不同类型的细胞因其独特的生物学特性而被广泛应用于多种疾病的治疗。以下是一些常用的细胞类型及其在细胞治疗中的应用。 （1）免疫细胞 免疫细胞是细胞治疗中最重要且研究最多的细胞类型之一，主要包括 T 细胞、自然杀伤细胞（NK 细胞）和树突状细胞（DC 细胞）。 T 细胞：T 细胞是人体免疫系统的核心细胞，具有强大的抗肿瘤能力。CAR-T 细胞疗法是目前最成功的免疫细胞治疗技术
简介 细胞增殖/细胞毒性测定是涉及培养细胞的研究中最常用的测试之一。 其是检查用于治疗的药物浓度的基本初步测试，也是确定各种研究领域（如肿瘤学和细胞死亡）药物疗效和安全性的非常重要的测试。 传统上，WST-8 或 ATP 检测（使用代谢活性作为指标）和 BrdU 或胸腺嘧啶核苷检测（使用 DNA 合成水平作为指标）已用于细胞生长特性的定量评估。 尽管这些检测由于其简易性和吞吐量而对我们有益，但这些检测都是间接评估方法，因此结果可能与实际细胞数无关。 在许多情况下，这些检测是终点评估，有时会
对于贴壁生长的细胞，相对来说比较简单但也很麻烦。以下我主要讨论贴壁生长的细胞。 在讨论之前，大家首先要有一个概念，即洁净区，并不是没有细菌，而是细菌的数量非常少，国家标准100级的洁净标准是浮游菌数不得超过5个每立方米，沉降菌数不得超过1个每培养皿.而国外的标准比我国的还要高一点，要求的数量更少。 所以在我们的洁净操作台里，并不是真正一个细菌都没有的，所以在操作的时候还是要尽量利索迅速地完成操作。尽量减少进入培养体系细菌的数量。 所以处理细菌污染的重要原则就是：无限地稀释细菌的浓度，无限地减少
技术资料